ABBV · 10-Q · 2026Q3 · Full report

Acquisition / Partnership / Divestiture

AbbVie Inc. · 2026-11-03 · Importance 59 · Surprise 60 · In source text

AbbVie’s investing cash flows included $10.6 billion of net cash payments for business acquisitions, primarily the Apogee Therapeutics acquisition, during the nine months ended September 30, 2026. The period also included $1.4 billion for other acquisitions and investments, net of cash acquired, and $1.1 billion of proceeds primarily from selling investment securities acquired with Apogee. Acquired IPR&D and milestone expense included a $650 million upfront charge for a license agreement with RemeGen Co., Ltd. AbbVie reported $431 million of acquisition and integration expenses for the nine-month period.

Key facts

• Acquired IPR&D and milestones expense for the three and nine months ended September 30, 2025 included upfront charges of $1.9 billion for the Capstan Therapeutics acquisition and $700 million for a license agreement with Ichnos Glenmark Innovation. source
• Acquired IPR&D and milestones expense for the nine months ended September 30, 2026 included a $650 million upfront charge related to a license agreement with RemeGen Co., Ltd. source
• Acquired IPR&D and milestones expense for the nine months ended September 30, 2025 included a $350 million upfront charge for a Gubra license agreement and a $335 million upfront charge for an ADARx option-to-license agreement. source

Impact estimates